Basel, Switzerland | February 2021
With a strong track record of success in the field of medicinal chemistry, SpiroChem has proven to be the ideal partner for biotech and pharma companies alike. But there is no place for complacency. SpiroChem’s mission is to keep innovating and bringing new concepts and solutions to advance and accelerate discovery chemistry. And for this, SpiroChem can count on its elite chemistry resources and growing network of advisors, the latest addition being Dr. Rob Young.
Rob Young will further reinforce SpiroChem’s extensive medicinal chemistry expertise. The blend of expertise and experience within our Scientific Advisory Team provides an indispensable role in supporting the continued success of SpiroChem’s medicinal chemistry discovery services.
Rob brings 30+ years of experience in drug discovery, which provides substantive hands on and leadership experience to provide consultancy service. His career encompassed work across all stages of the discovery process from program initiation, through hit/lead identification (using all methods from fragments, through ligand based design, HTS and DNA encoded libraries) and lead optimization to candidate selections across many targets and therapeutic areas. His pioneering work property based design, advocating low fat, low flat principles, is very much aligned to SpiroChem’s expertise in novel sp3-rich scaffolds and isosteres.
Rob was educated (MA, D. Phil) at the University of Oxford and undertook post-doctoral work at The University of Chicago before joining Wellcome, from where he navigated mergers and acquisitions in the formation of GSK during his industrial career. He took early retirement in 2019 and set up Blue Burgundy Ltd to pursue consulting and teaching interests in drug discovery.